Rheumatology

A Phase III clinical trial presented at ACR Convergence 2024 revealed that upadacitinib (UPA), combined with a 26-week glucocorticoid (GC) improved disease control and reduced steroid exposure compared to a placebo (PBO) regimen in patients with giant cell arteritis (GCA).

Presented at the ACR Convergence 2024, new research highlighted how changing global recruitment patterns influence placebo response rates in clinical trials for psoriatic arthritis (PsA).

In a groundbreaking study, once-weekly semaglutide injections were shown to significantly reduce both knee osteoarthritis pain and body weight in adults with obesity, offering promising new relief for patients with limited treatment options.

Recent findings have underscored the role of traumatic stress as a potent trigger for autoimmune rheumatic diseases (ARDs), emphasizing a feedback loop that perpetuates these conditions.

Systemic lupus erythematosus impacts placental health, particularly in pregnancies resulting in small for gestational age infants.

Hot and cold outdoor temperatures significantly worsen Raynaud’s phenomenon in patients with systemic sclerosis, according to new research.

Adoption of cutting-edge imaging technologies and innovative use of existing methods may revolutionize the diagnosis and treatment of inflammatory arthritis.

New study found that increasing secukinumab dosage to 300 mg provides no significant benefit for ankylosing spondylitis patients who did not respond to 150 mg.